SPRINGWORKS THERAPEUTICS INC (SWTX) Stock News

USA - NASDAQ:SWTX - US85205L1070 - Common Stock

46.99 USD

+0.01 (+0.02%)

Last: 6/30/2025, 8:00:01 PM

46.98 USD

-0.01 (-0.02%)

After Hours: 6/30/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SWTX Latest News, Press Relases and Analysis

All

Press Releases

2 months ago - By: SpringWorks Therapeutics, Inc.

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

2 months ago - By: SpringWorks Therapeutics, Inc.

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

2 months ago - By: Benzinga - Mentions: CPNG IWM SPY XLF ...

Legendary Investor Stanley Druckenmiller Made Huge AI And Chipmaker Bets In Q2 — Here's What He Knows That You Don't

2 months ago - By: Bloomberg

Merck KGaA Taps High-Grade Bond Market to Fund SpringWorks Buy

5 months ago - By: Rowley Law PLLC

News Image

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc.

5 months ago - By: Benzinga

Analyst Expectations For SpringWorks Therapeutics's Future

2 months ago - By: Bloomberg

Merck KGaA Plans $4 Billion Bond Sale to Fund SpringWorks Therapeutics Acquisition

3 months ago - By: SpringWorks Therapeutics, Inc.

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

3 months ago - By: SpringWorks Therapeutics, Inc.

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

4 months ago - By: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

4 months ago - By: Halper Sadeh LLC - Mentions: PRA OPOF

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPOF, PRA, SWTX on Behalf of Shareholders

4 months ago - By: Halper Sadeh LLC - Mentions: LNSR ICAD SSBK

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, SWTX, ICAD, SSBK on Behalf of Shareholders

4 months ago - By: Kahn Swick & Foti, LLC

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

5 months ago - By: Yahoo Finance

SpringWorks Therapeutics (SWTX) Surged on Acquisition News

5 months ago - By: Zacks Investment Research - Mentions: HALO LXRX AMRN

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

5 months ago - By: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics recibe un dictamen positivo del CHMP para el uso de mirdametinib en el tratamiento de la NF1-NP en pacientes adultos y pediátricos

5 months ago - By: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics: CHMP valuta positivamente Mirdametinib per il trattamento di pazienti adulti e pediatrici affetti da NF1-PN

5 months ago - By: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics krijgt positief advies van de CHMP voor Mirdametinib voor de behandeling van volwassen en pediatrische patiënten met NF1-PN

5 months ago - By: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN

5 months ago - By: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics reçoit un avis favorable du CMUH pour l’utilisation du mirdamétinib pour le traitement des patients adultes et pédiatriques atteints de NF1-PN

5 months ago - By: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

5 months ago - By: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

5 months ago - By: Halper Sadeh LLC - Mentions: NVEE CHTR INZY

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders

5 months ago - By: Halper Sadeh LLC - Mentions: AXL KRON PRA

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AXL, KRON, PRA, SWTX on Behalf of Shareholders

5 months ago - By: Zacks Investment Research - Mentions: CTMX

SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates

5 months ago - By: Zacks Investment Research - Mentions: HRMY

Harmony Biosciences Holdings, Inc. (HRMY) Tops Q1 Earnings and Revenue Estimates

5 months ago - By: Kahn Swick & Foti, LLC

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

5 months ago - By: Halper Sadeh LLC - Mentions: OPTN COEP CKPT

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, COEP, SWTX, CKPT on Behalf of Shareholders

5 months ago - By: Zacks Investment Research

Wall Street Analysts Believe SpringWorks Therapeutics (SWTX) Could Rally 42.29%: Here's is How to Trade

5 months ago - By: Yahoo Finance - Mentions: MRK DHI CMG

Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion

5 months ago - By: Ademi & Fruchter LLP

Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

5 months ago - By: Yahoo Finance - Mentions: NVDA SCHW ITT 2356 ...

Taiwan's Inventec to invest up to $85 million in US to lessen tariff impact

5 months ago - By: Halper Sadeh LLC

SWTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SpringWorks Therapeutics, Inc. Is Fair to Shareholders

6 months ago - By: Bloomberg

Merck KGaA to Buy US Drugmaker Springworks for $3.9 Billion